Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of maintenance olaparib plus bevacizumab vs standard chemotherapy-based maintenance in metastatic colorectal cancer
2019-000698-22Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival by BICR (RECIST 1.1). Started Sep 2019; status: completed.
02
Drugs
olaparib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-000698-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000698-22.